Immune-mediated necrotizing myopathy (IMNM) is a rare type of autoimmune inflammatory myopathy, which can be divided into anti-signal recognition particle antibody positive IMNM, anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibody positive IMNM and serum antibody negative IMNM according to different autoantibodies. The prognosis of IMNM is worse than that of most other types of myositis. At present, there are differences in the studies of prognostic factors of IMNM at home and abroad, and there is a lack of large-scale clinical studies. This article will review the prognostic factors of IMNM.
Immune-mediated necrotizing myopathy (IMNM) is a type of autoimmune myopathy characterized by relatively severe proximal weakness with high serum muscle enzyme levels, myofiber necrosis with minimal inflammatory cell infiltrate on muscle biopsy, and infrequent extra-muscular involvement. The mechanism of necrotizing myopathy remains unclear. The new European Neuromuscular Centre criteria divides IMNM into three distinct subtypes according to different autoantibodies, which reminds us antibodies may be involved in the pathogenesis of IMNM and different subtypes may have different pathogenesis. This review summarizes the current understanding of the pathogenesis of IMNM.
